18FDG-PET IMAGING IN CANINE LYMPHOMA AND CUTANEOUS MAST CELL TUMOR

  1. AMY K. LEBLANC1,
  2. BJOERN W. JAKOBY2,3,4,
  3. DAVID W. TOWNSEND2,
  4. GREGORY B. DANIEL5

Article first published online: 26 FEB 2009

DOI: 10.1111/j.1740-8261.2009.01520.x

Issue

Veterinary Radiology & Ultrasound

Veterinary Radiology & Ultrasound

Volume 50, Issue 2, pages 215–223, March/April 2009

Additional Information

How to Cite

LEBLANC, A. K., JAKOBY, B. W., TOWNSEND, D. W. and DANIEL, G. B. (2009), 18FDG-PET IMAGING IN CANINE LYMPHOMA AND CUTANEOUS MAST CELL TUMOR. Veterinary Radiology & Ultrasound, 50: 215–223. doi: 10.1111/j.1740-8261.2009.01520.x

Author Information

  1. 1

    Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN

  2. 2

    Molecular Imaging and Translational Research Program, Graduate School of Medicine, University of Tennessee, Knoxville, TN,

  3. 3

    Siemens Molecular Imaging, Knoxville, TN

  4. 4

    Department of Physics, University of Surrey, Guildford, Surrey, UK

  5. 5

    Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, VA, 24061

*Address correspondence and reprint requests to Amy K. LeBlanc, at the above address. E-mail: aleblanc@utk.edu

Publication History

  1. Issue published online: 26 FEB 2009
  2. Article first published online: 26 FEB 2009
  3. Received May 19, 2008; accepted for publication September 8, 2008.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (950K)

Keywords:

  • cancer;
  • canine;
  • molecular imaging

Positron Emission Tomography (PET) using the glucose analog 2-deoxy-2-[18F]fluoro-d-glucose (18FDG) is a common imaging modality for diagnosis and management of many human malignancies. We evaluated 18FDG-PET in dogs with either multicentric lymphoma (LSA) or cutaneous mast cell tumor (MCT). A prototype large field-of-view PET scanner was used to collect whole-body images in nine dogs with LSA or MCT. Both tumors were characterized by avidity for 18FDG. In dogs with LSA, 18FDG-PET correctly identified involvement of superficial and internal lymph nodes, liver, and spleen. Repeated PET scans after induction chemotherapy demonstrated resolution of abnormal 18FDG uptake within these sites. In dogs with MCT, 18FDG-PET correctly identified MCT metastasis to regional lymph nodes in all dogs in which this was suspected or confirmed with cytology or biopsy before the PET scan. In two dogs, additional sites of mast cell disease were identified with 18FDG-PET that were undetected on physical examination and/or regional lymph node cytology. 18FDG-PET holds promise as a whole-body staging method for canine LSA and MCT.

View Full Article (HTML) Get PDF (950K)